Evidence map›Paper›PMID 41034402›Full record

ArticleActa pharmacologica Sinica2026

Discovery and characterization of a novel HIF-2α agonist for the treatment of CKD-related renal anemia.

Shu-Qing Chu, Yi-Jie Chen, Rui-Rui Yang, Dan Teng, Gui-Zhen Zhou, Ying-Ying Zhang, Bu-Ying Niu, Jia-Hang Xu, Ke-Xin Lin, Xin-Yu Yang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shu-Qing Chu *School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Yi-Jie Chen *School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Rui-Rui Yang *University of Chinese Academy of Sciences, Beijing, 100049, China.
Dan TengDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Gui-Zhen ZhouDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Ying-Ying ZhangDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Bu-Ying NiuDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Jia-Hang XuDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Ke-Xin LinSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Xin-Yu YangSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Xu-Tong LiDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. lixutong@simm.ac.cn.
Ming-Yue ZhengSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China. myzheng@simm.ac.cn.
Su-Lin ZhangDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. slzhang@simm.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoxia-inducible factor 2-alpha (HIF-2α), a critical transcription factor, forms a heterodimer with aryl hydrocarbon receptor nuclear translocator (ARNT) to drive the transcription of erythropoietin (EPO), a key regulator of erythropoiesis. Activation of this pathway plays a pivotal role in the treatment of anemia. By discovered structure-based virtual screening and pharmacological assays, we herein discovered an amide thiazole AT-1 that bound to HIF-2α with a K

Indexed as

AnemiaBasic Helix-Loop-Helix ProteinsRenal Insufficiency, ChronicAnimalsAryl Hydrocarbon Receptor Nuclear TranslocatorDrug DiscoveryErythropoietinHumansMaleMiceMolecular Docking SimulationPyrazolesTriazolesZebrafishAryl Hydrocarbon Receptor Nuclear TranslocatorBasic Helix-Loop-Helix ProteinsErythropoietinmolidustatPyrazolesTriazolesamide thiazole AT-1anemiaaryl hydrocarbon receptor nuclear translocatorerythropoietinHIF-2αM1002Molidustat

Identifiers

PMID41034402
PMCPMC12811612

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.